Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …

Lung cancer is one of the most common cancers in the world. Although medical treatment
has made impressive progress in recent years, it is still one of the leading causes of cancer …

Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …

Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …

FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of
pembrolizumab and atezolizumab for similar indications as first-line treatment for patients …

Simple Summary The objective of the study was to assess the radiomics features obtained
by computed tomography (CT) examination as biomarkers in order to select patients with …

LKB1 and KRAS are the third most frequent co-mutations detected in non-small cell lung
cancer (NSCLC) and cause aggressive tumor growth. Unfortunately, treatment with RAS …